JS
Therapeutic Areas
Inovio Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INO-3107 | Recurrent Respiratory Papillomatosis (RRP) | BLA Submitted |
| VGX-3100 | HPV-Positive High-Grade Anal Lesions (HSIL) | Phase 2 |
| INO-5401 | Cancer Prevention in BRCA1/2 Mutation Carriers | Phase 1 |
| DMAb-1 / DMAb-2 | Prevention of COVID-19 | Phase 1 |
Leadership Team at Inovio Pharmaceuticals
PK
Peter Kies
Chief Financial Officer
MS
Michael Sumner, MB BS, MBA
Chief Medical Officer & Head of Development
LH
Laurent Humeau, Ph.D.
Chief Scientific Officer; Chairman, Scientific Advisory Board
SE
Steve Egge, MBA
Chief Commercial Officer
RC
Rob Crotty, J.D.
General Counsel, Corporate Secretary & Chief Compliance Officer
EB
EJ Brandreth, MBA
Senior Vice President, Quality Assurance
SB
Shawn Bridy, MA, MBA
Senior Vice President, Business Development
CE
Cheryl Elder, PharmD
Senior Vice President, Regulatory Affairs
RJ
Robert J. Juba Jr.
Senior Vice President, Biological Manufacturing and Clinical Supply Management
JS
Jeffrey Skolnik, M.D.
Senior Vice President, Clinical Development